SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors aggressively buy the dip following a sharp price drop, fueled by community speculation that Amazon's acquisition of Globalstar validates the direct-to-device satellite sector rather than signaling a competitive threat. Sentiment remains overwhelmingly bullish as the community focuses on the upcoming BlueBird 7 satellite launch, viewing recent volatility as a strategic opportunity to accumulate shares before potential institutional breakthroughs.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is surging as the market digests CEO Andy Jassy's shareholder letter, which revealed a massive AI revenue run rate and an aggressive commitment to infrastructure investment, signaling the company's evolution into a vertically integrated AI utility. While some investors are concerned about overextension and technical pullbacks, bullish sentiment is being fueled by strong institutional accumulation and strategic positioning in AI-driven cloud computing.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is currently experiencing heightened volatility and intense retail discussion following a short-seller hit piece that raised concerns about tax implications and commercialization delays. Despite the report triggering a sharp price decline, the community is actively pushing back by highlighting the company's strategic manufacturing pivot, robust cash position, and the critical role their photonics solutions play in alleviating data center bottlenecks for major industry partners.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is trending as the community closely monitors a critical definitive agreement with a major crypto exchange, with many investors anticipating a significant price surge tied to potential prediction market expansion. Enthusiastic traders are actively tracking technical levels, managing positions around short-interest dynamics, and debating the stock's long-term potential as a leader in a high-growth, regulated sector.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors digest news of successful metallurgical test work for its Tanbreez project while monitoring potential geopolitical tailwinds related to Greenland and strategic mineral supply chains. The community is actively debating the stock's valuation, the impact of short interest, and the role of algorithmic trading, with many bulls anticipating a significant re-rating driven by upcoming project milestones and potential strategic interest.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is currently in focus as investors closely track its strategic ETH accumulation and upcoming NYSE uplisting, which many in the community view as a potential catalyst for liquidity and price stability. Despite this, sentiment remains sharply divided, with intense debate ongoing between bulls optimistic about long-term institutional staking and bears expressing significant frustration over consistent share dilution and the stock's persistent trading discount to its net asset value.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing explosive momentum as investors front-run its upcoming inclusion into the Nasdaq-100 Index, fueling a massive institutional buying spree and a rapid surge toward the four-digit price mark. The community is heavily divided, with bulls pointing to the company's critical role in AI infrastructure and potential stock splits, while cautious traders and short sellers are debating whether this represents a sustainable re-rating or a classic parabolic blow-off top.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is surging as the market increasingly positions the company as a primary beneficiary of the AI data center power demand, with investors highlighting its ability to provide rapid, on-site energy solutions. Community sentiment remains highly bullish, fueled by aggressive institutional accumulation and positive long-term outlooks regarding the company's role in the global energy transition.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense trading activity as market speculation mounts regarding a potential acquisition by major tech players like Amazon or SpaceX to bolster satellite broadband and D2D capabilities. Investors are actively debating the long-term strategic value of the companys licensed spectrum assets and the complex integration hurdles posed by existing partnerships, with many long-term shareholders dismissing recent buyout rumors as significant undervaluation.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is experiencing significant volatility driven by a combination of market-wide risk-off sentiment and specific investor interest in the company's progress on photonic interconnects and strategic DARPA contracts. While the community remains polarized between those viewing current price levels as a long-term accumulation opportunity in quantum infrastructure and skeptics who emphasize ongoing valuation risks and cash burn, sentiment is currently heavily focused on the stock's role within broader quantum and AI sector rotations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere Therapeutics (NASDAQ:TVTX) Rating Increased to Overweight at Piper Sandler

Piper Sandler raised shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 target price for the company in a report on Tuesday...

Tuesday Sector Leaders: Biotechnology, Medical Instruments & Supplies

In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 3.4%. Leading the group were shares of Travere Therapeutics, up about 34.1% and shares of Insight Molecular Diagnostics up about 33% on the day.

Also showing relative strength are medical...

Travere Therapeutics (NASDAQ:TVTX) Given New $56.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday...

Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday

Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TVTX, BE, IONQ, SANA, RGTI, VACH, AOSL.read more...

Travere Therapeutics (NASDAQ:TVTX) Hits New 1-Year High Following Analyst Upgrade

Travere Therapeutics (NASDAQ:TVTX) Hits New 12-Month High After Analyst Upgrade...

Travere Therapeutics (NASDAQ:TVTX) Given New $44.00 Price Target at Wedbush

Wedbush upped their price objective on Travere Therapeutics from $39.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday...

Guggenheim Raises Travere Therapeutics (NASDAQ:TVTX) Price Target to $54.00

Guggenheim increased their price objective on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday...

<ul class="summary-bullets"><li>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis, a rare kidney disorder.</li><li>The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.</li><li>Citi does not see a commercial setback despite a narrower label, according to The Fly.</li></ul>Shares of Travere Therapeutics (TVTX) surged more than 40% in pre-market trading on Tuesday as bullish analyst reactions followed the U.S. Food and Drug Administration (FDA) approval of the company’s Filspari for a rare kidney disorder, making it the first approved treatment for the condition.If the premarket levels hold after the opening bell, <a href="https://stocktwits.com/symbol/TVTX">TVTX shares</a> would surge to their highest since May 2005.<h2 class="st-heading-2">Filspari Becomes The Only Approved FSGS Treatment</h2>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis (FSGS). FSGS is a serious condition that causes protein leakage in urine, leading to progressive kidney damage and potential failure. The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.The decision follows a delayed review prompted by the FDA's request for additional data. Approval was supported by late-stage trial results showing Filspari reduced proteinuria by 48% over 108 weeks.Brokerages turned bullish on Travere Therapeutics following the FDA approval. Canaccord raised its price target to $56 from $47 and maintained a ‘Buy’ rating, according to The Fly, projecting peak sales of $547 million for the drug by 2032.Citi analyst Yigal Nochomovitz increased the firm’s price target to $53 from $48, keeping a ‘Buy’ rating. Citi said the approval in FSGS supports the increased target, adding that the narrower label is not seen as a commercial setback. Bank of America also lifted its target to $49 from $44 and reiterated a ‘Buy’ rating on the stock.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours. Messages on the platform increased a whopping 3,200% during the same period, according to Stocktwits data.&nbsp;&nbsp;One user expects “swift uptake for this medicine.”<stembedurl>https://stocktwits.com/pblegend66/message/650201899</stembedurl>Year-to-date, the stock has slid around 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment

Canaccord projected peak sales of $547 million for the drug by 2032, according to The Fly.

Equity

HC Wainwright Reiterates Buy Rating for Travere Therapeutics (NASDAQ:TVTX)

HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a report on Tuesday...

<ul><li>The agency approved the drug in adult and pediatric patients aged 8 years and older.</li><li>Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome. &nbsp;</li><li>Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy.</li></ul>Travere Therapeutics, Inc. (TVTX) said on Monday that the U.S. Food and Drug Administration has approved its Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis (FSGS), making it the first FDA-approved drug for the indication.The agency approved the drug in adult and pediatric patients aged 8 years and older. Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome.Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units.<h2 class="st-heading-2">Fresh Approval</h2>While the FDA was previously expected to decide on Travere’s application by January, it pushed it to April after requesting additional information to assess Filspari’s clinical benefit. The company submitted responses, and the agency determined that the responses constitute a major amendment to the application, and extended the review timeline.Filspari was approved in the new indication based on data from a late stage trial where FSGS patients without nephrotic syndrome who were treated with Filspari experienced a 48% reduction in proteinuria from baseline to week 108 compared to 27% for those treated with irbesartan.FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure.While TVTX edged 0.2% lower after hours, shares of Ligand Pharmaceuticals (LGND), with which Travere has a licensing agreement for Sparsentan, sold under the Filspari brand, rose 3% at the time of writing.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TVTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/TVTX">TVTX</a> has gained 107% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/aal-stock-advances-after-hours-following-report-of-ual-ceo-combining-his-past-and-present-companies/cZJ8WmWRIuC">AAL Stock Advances After-Hours Following Report Of UAL CEO Combining His Past And Present Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease

The FDA approved Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Buying - this rally is real

Trimming - locking in some gains

Selling out - using strength to exit

Holding and hoping

The market has been ripping higher - what&#39;s your move now?

Stocktwits

The market has been ripping higher - what's your move now?

Stocktwits Polls

Investors are celebrating the long-awaited FDA approval of Filspari as the first and only treatment for FSGS kidney disease.

Traders are closely monitoring the potential for a massive short squeeze as massive institutional ownership clashes with limited retail float.

Major analysts including Guggenheim and Canaccord have rapidly increased price targets to $54-$56 following the drug's label expansion.

Projections estimate a multibillion-dollar addressable market for the drug due to higher dosing and lack of direct competition.

Current Price	$41.03
Prev Close	$30.70
Open	$41.23
Dividend Yield	0.00%
50-Day Moving Average	$29.31
Beta	1.51
Avg. Volume	1.25M
PE Ratio	-50.91

52-Week High	$42.13
52-Week Low	$13.88
Market Capitalization	$2.83B
EPS (Annual)	-$0.5634
Price to Book	24.31
Revenue Per Employee	$987,380.28

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TVTX News

TVTXTravere Therapeutics Inc